Advisors Management Group Inc. ADV Has $3 Million Stake in Amgen Inc. (AMGN)
Advisors Management Group Inc. ADV grew its position in Amgen Inc. (NASDAQ:AMGN) by 2.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,434 shares of the medical research company’s stock after acquiring an additional 444 shares during the period. Amgen comprises 1.7% of Advisors Management Group Inc. ADV’s portfolio, making the stock its 28th largest holding. Advisors Management Group Inc. ADV’s holdings in Amgen were worth $3,003,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of the company. PGGM Investments boosted its holdings in Amgen by 2.3% during the second quarter. PGGM Investments now owns 670,936 shares of the medical research company’s stock worth $115,555,000 after buying an additional 15,059 shares in the last quarter. Shelton Capital Management boosted its holdings in Amgen by 82.7% during the first quarter. Shelton Capital Management now owns 108,997 shares of the medical research company’s stock worth $17,883,000 after buying an additional 49,354 shares in the last quarter. Greylin Investment Mangement Inc. boosted its holdings in Amgen by 466.9% during the second quarter. Greylin Investment Mangement Inc. now owns 14,030 shares of the medical research company’s stock worth $2,416,000 after buying an additional 11,555 shares in the last quarter. Kelman Lazarov Inc. boosted its holdings in Amgen by 8.2% during the second quarter. Kelman Lazarov Inc. now owns 1,580 shares of the medical research company’s stock worth $272,000 after buying an additional 120 shares in the last quarter. Finally, Osborne Partners Capital Management LLC boosted its holdings in Amgen by 0.5% during the second quarter. Osborne Partners Capital Management LLC now owns 17,023 shares of the medical research company’s stock worth $2,932,000 after buying an additional 91 shares in the last quarter. 78.13% of the stock is currently owned by institutional investors and hedge funds.
In related news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.19% of the company’s stock.
A number of research firms recently commented on AMGN. Morgan Stanley decreased their price objective on shares of Amgen from $196.00 to $193.00 and set an “overweight” rating on the stock in a report on Thursday, October 26th. Mizuho set a $198.00 price objective on shares of Amgen and gave the stock a “buy” rating in a report on Sunday, October 29th. Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Argus downgraded shares of Amgen from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $175.22 to $195.00 in a report on Wednesday. Finally, BMO Capital Markets reissued a “market perform” rating and set a $198.00 price objective on shares of Amgen in a report on Thursday, October 26th. Thirteen analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Amgen presently has a consensus rating of “Buy” and a consensus price target of $190.03.
Amgen Inc. (NASDAQ AMGN) opened at $173.44 on Friday. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $191.10. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07. The company has a market cap of $125,902.01, a P/E ratio of 13.79, a P/E/G ratio of 2.52 and a beta of 1.37.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The firm had revenue of $5.77 billion during the quarter, compared to analyst estimates of $5.75 billion. During the same quarter in the prior year, the business posted $3.02 earnings per share. Amgen’s revenue for the quarter was down .7% compared to the same quarter last year. equities research analysts expect that Amgen Inc. will post 12.64 EPS for the current fiscal year.
Amgen declared that its Board of Directors has approved a stock repurchase program on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be given a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.65%. The ex-dividend date is Thursday, November 16th. Amgen’s dividend payout ratio (DPR) is 41.63%.
TRADEMARK VIOLATION NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/advisors-management-group-inc-adv-has-3-million-stake-in-amgen-inc-amgn/1679629.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.